Screener
Allogene Therapeutics ALLO Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
The source filing: Allogene Therapeutics’s 10-Q, filed August 12, 2026. Open the filing →
- Filed
- Aug 12, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-056213
FAQ
- What is Allogene Therapeutics's free cash flow?
- Allogene Therapeutics (ALLO) reported free cash flow of -$32.15M in Q2 2026.
- How has Allogene Therapeutics's free cash flow changed year-over-year?
- Allogene Therapeutics's free cash flow increased by 17.7% year-over-year, from -$39.07M to -$32.15M.
- What is the long-term trend for Allogene Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Allogene Therapeutics's free cash flow has grown at a -7.7% compound annual growth rate (CAGR), from -$206.26M to -$149.63M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Allogene Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude